This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Faries, D. E. Articles by Heiligenstein, J. H. Search for Related Content PubMed Articles by Faries, D. E. Articles by Heiligenstein, J. H. Social Bookmarking                         What's this?

Validation of the ADHD Rating Scale as a clirlician administered and scored instrument

Eli Lilly and Company

Ilker Yalcin

Eli Lilly and Company

Donald Harder

Eli Lilly and Company

John H. Heiligenstein

Eli Lilly and Company

There are several parent- and teacher-scored rating scales that are validated and available for assessing the severity of ADHD symptoms in pediatric populations. However, we are not aware of any symptom severity rating scales with published validation results when administered and scored by clinicians following a semi-structured interview with the parent or guardian.

In a recent clinical trial, in order to have consistency in assessing entry severity criteria and changes in symptom severity over time across patients, we used the ADHD Rating Scale, administered and scored by trained clinicians. Using data from this trial, we assessed the validity and reliability of the ADHD Rating Scale when completed by trained clinicians based on interviews with parents.

Results Indicate that this version of the scale has acceptable levels of inter-rater reliability, test-retest reliability, internal consistency, convergent validity, discriminant validity, and responsiveness. The psychometric properties were comparable to other validated scales for assessing ADHD symptom severity. Overall, this study supports the use of the ADHD Rating Scale as a clinician administered and scored tool for assessing the severity of ADHD symptoms in pediatric patients.

Journal of Attention Disorders, Vol. 5, No. 2, 107-115 (2001)
DOI: 10.1177/108705470100500204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Popovic, P. Bhattacharya, and L. Sivaswamy Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder Am. J. Health Syst. Pharm., November 15, 2009; 66(22): 2005 - 2012. [Abstract] [Full Text] [PDF]

				B. J Cowles Lisdexamfetamine for Treatment of Attention-Deficit/Hyperactivity Disorder Ann. Pharmacother., April 1, 2009; 43(4): 669 - 676. [Abstract] [Full Text] [PDF]

				M. Johnson, S. Ostlund, G. Fransson, B. Kadesjo, and C. Gillberg Omega-3/Omega-6 Fatty Acids for Attention Deficit Hyperactivity Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents J Atten Disord, March 1, 2009; 12(5): 394 - 401. [Abstract] [PDF]

				T. E. Wilens, K. McBurnett, O. Bukstein, J. McGough, L. Greenhill, M. Lerner, M. A. Stein, C. K. Conners, J. Duby, J. Newcorn, et al. Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 82 - 90. [Abstract] [Full Text] [PDF]